A potential COVID-19 EUA could turn this small biotech into a household name

Veru’s CEO discusses the impact of the upcoming FDA decision on its treatment targeting severely ill COVID-19 patients.

By Meagan Parrish • May 19, 2022

Woman of the Week: Sparrow Pharmaceuticals' Jamie MacPherson

The vice president of regulatory affairs and quality on embracing leadership challenges in drug development.

By Taren Grom • May 18, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Jumping into pharma with big plans at a small company

SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.

By Alexandra Pecci • May 17, 2022

Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

By Michael Gibney • May 17, 2022

Are digital DCTs the answer for rare diseases?

How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.

By Kim Ribbink • May 16, 2022

After 40 years, researchers discover new frontiers in the fight against HIV

Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.

By Karissa Waddick • May 16, 2022

Why 'soft' skills matter in the new era of leadership

Standout leaders honored by the Healthcare Businesswomen's Association discuss the rising value of the interpersonal approach.

By Taren Grom • May 12, 2022

With the shine of amyloid fading, tau is a rising star in Alzheimer's

The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.

By Michael Gibney • May 11, 2022

In the hot pharma talent market, execs battle these recruitment misconceptions

One of the top recruiting firms in life sciences weighs in on how companies can attract the next wave of rising stars.

By Meagan Parrish • May 11, 2022

It's time to acknowledge access as a prescribing barrier

A new survey reveals how red tape limits patient access to doctor-preferred specialty drugs. 

By Karissa Waddick • May 11, 2022

FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have

New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.

By Kelly Bilodeau • May 10, 2022

Where hope and uncertainty meet: A cutting-edge cancer developer's winding road

Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.

By Alexandra Pecci • May 9, 2022

Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

By Taren Grom • May 9, 2022

Ultra-sensitive tests bring biomarkers into the drug development forefront

An agreement between the biomarker assay maker Quanterix and pharma giant Eli Lilly could help discover new ways to treat Alzheimer's.

By Michael Gibney • May 5, 2022

Pharma's solution to the digital advertising dilemma? Storytelling

Peter Shin, vice president of Client Services at Sonic Health, says quality storytelling, rather than trendy content, is central to a digital advertising strategy.

By Karissa Waddick • May 5, 2022

Breaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine

After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.

By Taren Grom , Karissa Waddick • May 4, 2022

One company's failed drug is this company's 'jewel'

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

By Meagan Parrish • May 2, 2022

The 'innovation gap' haunts Big Pharma, and the race is on for the next blockbusters

The next big innovation wave is out there, and as pharmas expect massive losses without enough internal R&D to fill those shoes, smaller biotechs beckon.

By Michael Gibney • April 28, 2022

Mouse vs. machine: Using AI to solve the animal testing model in pharma

Quris is bringing its first drug tested preclinically using AI — rather than animal models — into human trials.

By Michael Gibney • April 26, 2022

How OliX Pharmaceuticals is riding the RNAi wave

While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

By Karissa Waddick , Taren Grom • April 25, 2022

Dispelling the 5 myths of biopharma brand planning

Many biopharma marketers have worked for more than one company during their career. 

April 25, 2022

From the fringes to the forefront — the mRNA era has taken hold of pharma

A look at what’s next for the industry’s buzziest technology.

By Kim Ribbink • April 22, 2022

Woman of the Week: Aura Biosciences' Dr. Elisabet de los Pinos

Dr. Elizabet de los Pinos, CEO and founder of Aura Biosciences, had a dream at a young age to change the course of cancer treatment and understand the underlying DNA of the disease.

By Taren Grom • April 20, 2022

With Lilly on board, Entos' medical chief champions genetic platform with 'unlimited' potential

 Steve Chen is helping to lead Entos through an ‘inflection point’ in the development of its precision medicine delivery platform.

By Alexandra Pecci • April 14, 2022

What now? Alzheimer's drugmakers ponder the path to approval

Why Medicare’s unprecedented decision to limit coverage for Aduhelm could have a chilling effect on Alzheimer’s R&D.

By Kelly Bilodeau • April 14, 2022